VERSION SHOWING CHANGES MADE

37. The recombinant BLNK protein according to Claim 35, wherein said BLNK protein [will bind] binds to a protein selected from the group consisting of Grb2, PLCγ, Vav, and Nck.

41. The recombinant BLNK protein according to Claim 39, wherein said BLNK protein [will bind] binds to a protein selected from the group consisting of Grb2, PLCγ, Vav, and Nck.

44. A method for screening for a bioactive agent [capable of binding] which binds to a BLNK protein, comprising:

a) combining a BLNK protein and a candidate bioactive agent; and

b) determining the binding of said candidate bioactive agent to said BLNK protein; wherein said BLNK protein comprises an amino acid sequence having at least about 95% identity to the amino acid sequence set forth in SEQ ID NO:1 and [will bind] binds to a protein selected from the group consisting of Grb2, PLCγ, Vav, and Nck in the absence of said candidate bioactive agent.

45. A method for screening for a bioactive agent [capable of modulating] which modulates the activity of a BLNK protein, comprising:

a) combining a BLNK protein, a candidate bioactive agent, and a BLNK binding partner selected from the group consisting of Grb2, PLCγ, Vav, and Nck; and

b) determining the binding of said BLNK protein to said BLNK binding partner;

wherein said BLNK protein comprises an amino acid sequence having at least about 95% identity to the amino acid sequence set forth in SEQ ID NO:1, wherein said BLNK protein [will bind] binds to said BLNK binding partner in the absence of a candidate bioactive agent, and wherein a decrease in the binding of said BLNK protein to said BLNK binding partner in the presence of said candidate bioactive agent indicates that said candidate bioactive agent is [capable of modulating] which modulates the activity of a BLNK protein.